Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia-Reference-Cited by-同舟云学术

Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia

Published:2019-05-04 Issue:5 Volume:18 Page:403-414
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Khoury Etienne¹,Brisson Diane¹,Roy Nathalie¹²,Tremblay Gérald²,Gaudet Daniel¹²

Affiliation:

1. Clinical Lipidology and Rare Lipid Disorders Unit, Community Genomic Medicine Center, Department of Medicine, Université de Montréal and ECOGENE-21 Clinical and Translational Research Center, Chicoutimi, Canada

2. Lipid Clinic, Chicoutimi Hospital, Chicoutimi, Canada

Funder

paper was not

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2019.1602606

Reference93 articles.

1. Homozygous familial hypercholesterolaemia

2. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment

3. Epidemiology of familial hypercholesterolaemia: Community and clinical

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lomitapide repurposing for treatment of malignancies: A promising direction;Heliyon;2024-06

2. Emerging therapies for refractory hypercholesterolemia: a narrative review;Future Cardiology;2024-04-25

3. Special Patient Populations;Clinical Lipidology;2024

4. Angiopoietin-like 3: An important protein in regulating lipoprotein levels;Best Practice & Research Clinical Endocrinology & Metabolism;2023-05

5. Atherosclerotic plaque regression in homozygous familial hypercholesterolaemia: a case report of a long-term lipid-lowering therapy involving LDL-receptor-independent mechanisms;European Heart Journal - Case Reports;2022-12-27